[Leu31-Pro34] neuropeptide Y identifies a subtype of 125I-labeled peptide YY binding sites in the rat brain

https://doi.org/10.1016/0197-0186(92)90067-2Get rights and content

Abstract

Subtypes of the neuropeptide Y (NPY) receptor in the rat brain were identified by the use of the selective Y-1 analog, [Leu31-Pro34] NPY. In rat brain homogenate binding studies, [Leu31-Pro34] NPY was found to produce a partial inhibition of 100 pM 125I-labeled peptide YY (PYY) binding with a plateau at 50 1000 nM [Leu31-Pro34] NPY resulting in a 70% inhibition of binding. The C-terminal fragment NPY 13–36, a putative Y-2 agonist, exhibited very little selectivity in rat brain homogenates. Scatchard analysis of 125I-labeled PYY binding to rat brain homogenate yielded biphasic plots with Kd values of 40 and 610 pM. Inclusion of 100 nM [Leu31-Pro34] NPY was found to eliminate the low affinity component of 125I-labeled PYY binding leaving a single, high affinity binding site with a Kd of 68 pM. In autoradiographic studies, displacement curves indicated that [Leu31-Pro34] NPY completely inhibited binding in the cerebral cortex with little effect on the binding in the hypothalamus. On the other hand NPY 13–36 inhibited binding in the hypothalamus at low concentrations but required higher concentrations to inhibit binding in the cerebral cortex. Other brain regions such as the hippocampus, appeared to contain both subtypes. Subsequent to these studies, a quantitative autoradiographic map was conducted using 50–100 pM 125I-labeled PYY in the presence and absence of [Leu31-Pro34] NPY which produced a selective displacement of binding in certain distinct brain regions. These areas included the cerebral cortex, certain thalamic nuclei and brainstem while ligand binding was retained in other brain regions including the zona lateralis of the substantia nigra, lateral septum, nucleus of the solitary tract and the hippocampus. Numerous brain regions appeared to contain both receptor subtypes. Therefore, the Y-1 and Y-2 receptor subtypes exhibited a somewhat distinct distribution in the brain. In addition, 125I-labeled PYY appears to label the Y-2 receptor with relatively higher affinity when compared to the Y-1 receptor.

References (86)

  • Y. Dumont et al.

    Differential distribution of neuropeptide Y1 and Y2 receptors in rat brain

    Eur. J. Pharmac.

    (1990)
  • R. Ekman et al.

    Peptide YY-like immuno-reactivity in the central nervous system of the rat

    Regul. Pept.

    (1986)
  • J.F. Flood et al.

    Modulation of memory processing by neuropeptide Y

    Brain Res.

    (1987)
  • T.S. Gray et al.

    Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system

    Life Sci.

    (1986)
  • A. Härfstrand et al.

    Inhibitory effects of neuropeptide Y on cyclic AMP accumulation in slices of the nucleus tractus solitarius region of the rat

    Neurosci. Lett.

    (1987)
  • D. Harland et al.

    Cardiovascular actions of neuropeptide Y in the hypothalamic paraventricular nucleus of conscious Long Evans and Brattleboro rats

    Neurosci. Lett.

    (1988)
  • M. Heilig et al.

    Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with alpha-adrenoceptors

    Eur. J. Pharmac.

    (1988)
  • M. Herkenham

    Mismatches between neurotransmitter and receptor localization in brain: observations and implications

    Neuroscience

    (1987)
  • J. Hinson et al.

    Neuropeptide Y stimulates inositol phospholipid hydrolysis in rat brain miniprisms

    Brain Res.

    (1988)
  • T. Hökfelt et al.

    Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons of the human medulla oblongata

    Neurosci. Lett.

    (1983)
  • F.B. Jolicoeur et al.

    In vivo structure activity study supports the existence of heterogeneous neuropeptide Y receptors

    Brain Res. Bull.

    (1991)
  • S.P. Kalra et al.

    Norepinephrine-like effects of neuropeptide Y on LH release in the rat

    Life Sci.

    (1984)
  • S.P. Kalra et al.

    Continuous intraventricular infusion of neuropeptide Y evokes episodic food intake in satiated female rats: effects of adrenalectomy and cholecystokinin

    Peptides

    (1988)
  • W.J. Kuenzel et al.

    Robust feeding following central administration of neuropeptide Y or peptide YY in chicks, Gallus domesticus

    Peptides

    (1987)
  • M.J. Kuhar

    The mismatch problem in receptor mapping

    Trends Neurosci.

    (1985)
  • S.F. Leibowitz et al.

    Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose

    Brain Res. Bull.

    (1988)
  • J.M. Lundberg et al.

    Neuropeptide Y- and alpha-adrenergic receptors in pig spleen: localization, binding characteristics, cyclic AMP effects and functional responses in control and denervated animals

    Neuroscience

    (1988)
  • J.-C. Martel et al.

    Comparative distribution of neuropeptide Y immunoreactivity and receptor autoradiography in rat forebrain

    Peptides

    (1988)
  • J.-C. Martel et al.

    Quantitative autoradiographic distribution of [125I]Bolton-Hunter neuropeptide Y receptor binding sites in rat brain

  • M.C. Michel

    Receptors for neuropeptide Y: multiple subtypes and multiple second messengers

    Trends Pharmac. Sci.

    (1991)
  • J.E. Morley et al.

    Peptide YY, a potent orexigenic agent

    Brain Res.

    (1985)
  • T.L. O'Donohue et al.

    Neuropeptide Y and peptide YY in neuronal and endocrine systems

    Peptides

    (1985)
  • T.M. Perney et al.

    Two different G-proteins mediate neuropeptide Y and bradykinin-stimulated phospholipid breakdown in cultured rat sensory neurons

    J. biol. Chem.

    (1989)
  • E.K. Potter et al.

    [Pro34]neuropeptide Y selectively identifies postjunctional-mediated actions of neuropeptide Y in vivo in rats and dogs

    Eur. J. Pharmac.

    (1991)
  • M.E. de Quidt et al.

    Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system II. Immunohistochemical analysis

    Neuroscience

    (1986)
  • N.A. Scott et al.

    The cardiovascular actions of centrally administered neuropeptide Y

    Regul. Pept.

    (1989)
  • S.P. Sheikh et al.

    Structural characterization of Y1 and Y2 receptors for neuropeptide Y and peptide YY by affinity cross-linking

    J. biol. Chem.

    (1990)
  • S.P. Sheikh et al.

    Y1 and Y2 receptors for neuropeptide Y

    FEBS Lett.

    (1989)
  • S.P. Sheikh et al.

    Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines

    J. biol. Chem.

    (1989)
  • B.G. Stanley et al.

    Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus

    Life Sci.

    (1984)
  • B.G. Stanley et al.

    Paraventricular injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion

    Peptides

    (1985)
  • C. Wahlestedt et al.

    Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides

    Regul. Peptides

    (1986)
  • C. Wahlestedt et al.

    Neuropeptide Y (NPY) and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders

    Prog. Neuropsychopharmac. biol. Psychiat.

    (1989)
  • Cited by (70)

    • What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands

      2019, Pharmacology and Therapeutics
      Citation Excerpt :

      It is involved in the regulation of decreased anxiety and depression (Caberlotto et al., 1999; Wahlestedt, Pich, Koob, Yee, & Heilig, 1993). The Y2 receptor is expressed in nerve fibers, the hippocampus, and intestine (Gehlert, Gackenheimer, & Schober, 1992; Rettenbacher & Reubi, 2001; Stjernquist & Owman, 1990), and it is associated with memory retention and angiogenesis (Flood & Morley, 1989; Zukowska-Grojec et al., 1998). The Y5 receptor is expressed in the hypothalamus, intestine, ovary, testis, pancreas, and skeletal muscle (Gerald et al., 1996; Herzog et al., 1997).

    • A cleavable cytolysin-neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action

      2015, Journal of Controlled Release
      Citation Excerpt :

      In a 96-well plate 5 × 104 cells were incubated with 125I-PYY (Perkin Elmer) at a final concentration of 60 pM (in 1% BSA/bidest. H2O (w/v), calculated based on specific radioactivity, corresponds to Kd [14]) and increasing concentrations of cold peptide (in 1% BSA/bidest. H2O (w/v)) for 60 min at room temperature under continuous shaking.

    • Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties

      2007, Biochemical Pharmacology
      Citation Excerpt :

      HEK293 cells expressing the chimeric receptors and AV12 cells expressing the wild-type receptors stably, were washed once with phosphate-buffered saline (PBS) and pelleted in fresh PBS. Radioligand-binding assays were conducted on isolated crude membrane homogenates as previously described [18] using [125I]-PYY as radioligand. Nonspecific binding was defined as the amount of radioactivity remaining on the filter after incubating with 0.1 μM human PYY (Bachem).

    View all citing articles on Scopus
    View full text